Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 4
1960 16
1961 23
1962 31
1963 48
1964 45
1965 45
1966 57
1967 42
1968 57
1969 41
1970 80
1971 64
1972 58
1973 74
1974 87
1975 96
1976 104
1977 80
1978 95
1979 96
1980 93
1981 108
1982 92
1983 99
1984 104
1985 100
1986 98
1987 88
1988 75
1989 73
1990 71
1991 53
1992 54
1993 50
1994 54
1995 55
1996 42
1997 30
1998 28
1999 42
2000 29
2001 36
2002 26
2003 34
2004 34
2005 28
2006 39
2007 32
2008 30
2009 29
2010 24
2011 21
2012 33
2013 36
2014 37
2015 22
2016 24
2017 30
2018 24
2019 13
2020 23
2021 27
2022 25
2023 32
2024 22
2025 26
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,325 results

Results by year

Filters applied: . Clear all
Page 1
[FLUPHENAZINE].
LEDEREROVA E. LEDEREROVA E. Cesk Psychiatr. 1965 Feb;61:63-5. Cesk Psychiatr. 1965. PMID: 14345579 Review. Czech. No abstract available.
Fluphenazine.
Rabinowitz D. Rabinowitz D. S Afr Med J. 1984 May 12;65(19):752. S Afr Med J. 1984. PMID: 6719308 No abstract available.
Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.
Tardy M, Huhn M, Engel RR, Leucht S. Tardy M, et al. Cochrane Database Syst Rev. 2014 Aug 3;2014(8):CD009230. doi: 10.1002/14651858.CD009230.pub2. Cochrane Database Syst Rev. 2014. PMID: 25087165 Free PMC article.
However, at least one movement disorder occurred significantly more frequently in the fluphenazine group (fluphenazine 15%, low-potency antipsychotics 10%, 3 RCTs, n = 971, RR 2.11 CI 1.41 to 3.15, low quality of evidence). ...The results of the primary outcome were …
However, at least one movement disorder occurred significantly more frequently in the fluphenazine group (fluphenazine 15%, lo …
Should we be Prescribing Fluphenazine Long-Acting Injectable Formulation?
Rowland D. Rowland D. Curr Psychiatry Rep. 2025 Jun;27(6):408-414. doi: 10.1007/s11920-025-01610-y. Epub 2025 Apr 28. Curr Psychiatry Rep. 2025. PMID: 40289033 Free PMC article. Review.
PURPOSE OF REVIEW: This review critically examines the clinical utility, efficacy, and tolerability of fluphenazine long-acting injectable (LAI) relative to contemporary alternatives. It further evaluates whether fluphenazine LAI confers substantive advantages over …
PURPOSE OF REVIEW: This review critically examines the clinical utility, efficacy, and tolerability of fluphenazine long-acting injec …
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T. Midha KK, et al. J Psychiatry Neurosci. 1994 Jul;19(4):254-64. J Psychiatry Neurosci. 1994. PMID: 7918346 Free PMC article. Review.
The effects of route of administration on the pharmacokinetics of fluphenazine and some of its metabolites; 2. The clinical pharmacokinetics of fluphenazine in acute patients medicated with oral fluphenazine; 3. ...These data illustrate the effect of "first p …
The effects of route of administration on the pharmacokinetics of fluphenazine and some of its metabolites; 2. The clinical pharmacok …
Fluphenazine decanoate (depot) and enanthate for schizophrenia.
Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE. Maayan N, et al. Cochrane Database Syst Rev. 2015 Feb 5;2015(2):CD000307. doi: 10.1002/14651858.CD000307.pub2. Cochrane Database Syst Rev. 2015. PMID: 25654768 Free PMC article.
No study comparing fluphenazine decanoate with oral neuroleptics reported death or hospital admissions.No significant difference in relapse rates in the medium term between fluphenazine decanoate and fluphenazine enanthate was found (n = 49, 1 RCT, RR 2.43, C …
No study comparing fluphenazine decanoate with oral neuroleptics reported death or hospital admissions.No significant difference in r …
Depot fluphenazine: risk/benefit ratio.
Glazer WM. Glazer WM. J Clin Psychiatry. 1984 May;45(5 Pt 2):28-35. J Clin Psychiatry. 1984. PMID: 6370986 Review.
The risks and benefits associated with depot fluphenazine are reassessed by a review and critique of the literature, with an emphasis on controlled studies comparing depot to oral preparations. ...
The risks and benefits associated with depot fluphenazine are reassessed by a review and critique of the literature, with an emphasis …
Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR. Ereshefsky L, et al. J Clin Psychiatry. 1984 May;45(5 Pt 2):50-9. J Clin Psychiatry. 1984. PMID: 6143748 Review.
The clinical significance of plasma monitoring of depot fluphenazine, including the development of dosage conversion guidelines, is presented. The relationships between haloperidol and its metabolite reduced haloperidol (RH) are discussed in terms of dosage form and respon …
The clinical significance of plasma monitoring of depot fluphenazine, including the development of dosage conversion guidelines, is p …
Psychophamacological treatment.
Marriott P. Marriott P. Schizophr Bull. 1976;2(4):505-6. doi: 10.1093/schbul/2.4.505-a. Schizophr Bull. 1976. PMID: 1019592 No abstract available.
Psychiatrists and citizens.
Samuel G. Samuel G. Br J Psychiatry. 1991 Nov;159:730. doi: 10.1192/bjp.159.5.730a. Br J Psychiatry. 1991. PMID: 1756363 Clinical Trial. No abstract available.
3,325 results